According to FDA, a study for Medtronic's deep-brain stimulation system for epilepsy treatment failed to meet a study goal. The goal was regarding a reduction in the rate of seizures over a three-month span. The agency did concede, however, that in the third month of treatment, Medtronic's system did reduce the rate of seizures compared with patients not using an activated device.

The system is already FDA approved for the treatment of Parkinson's disease, OCD, and several movement disorders. On Friday, FDA's neurological devices panel will review the device.